Effect of Gemfibrozil on the Pharmacokinetics of Mitiglinide in Rats

Abstract

A sensitive and specific method was developed and validated for the determination of mitiglinide in plasma using LC-MS/MS. The effect of gemfibrozil on the pharmacokinetics of orally administered mitiglinide in rats was investigated. The validated method in positive electrospray ionization mode using MRM and fully validated according to commonly accepted criteria. The desired sensitivity of mitiglinide was achieved with an LOQ of 0.5 ng/mL and the short run time was suitable for analysis of the large batches of samples. The method was successfully used to analyze rats plasma samples for application in pharmacokinetic studies. Pharmacokinetic parameters of mitiglinide were determined in rats following oral (0.25, 0.5, 1 mg/kg) administration to rats in the presence and absence of gemfibrozil (1 mg/kg). Compared to those animals in an oral control group (given mitiglinide alone), the area under the plasma concentration-time curve (AUC) of mitiglinide were increased significantly by 2.8, 3.5, 4.1-fold (0.25, 0.5, 1 mg/kg) by gemfibrozil, respectively. Consequently, the bioavailability of mitiglinide in the presence of gemfibrozil was significantly enhanced compared to that in oral control group (only mitiglinide). Gemfibrozil significantly enhanced the oral bioavailability of mitiglinide, suggesting that concurrent use of gemfibrozil and mitiglinide should be monitored closely for potential drug interactions.

Key words

gemfibrozil - mitiglinide - pharmacokinetics

• References

• 1 Sunaga Y, Gonoi T, Shibasaki T et al. The effects of mitiglinide KAD-1229, a new antidiabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001; Nov 9; 431 (01) 119-125
• 2 Reimann F, Proks P, Ashcroft FM. Effect of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and on Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 2001; Apr; 132 (07) 1542-1548
• 3 Liang Y, Sun J, Xie L et al. Simple, sensitive, and rapid LC-ESI-MS method for quantification of mitiglinide in human urine. Chromatographia 2007; 66: 165
• 4 Ojima K, Kiyono Y, Kojima M. Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset. Yakurigaku Zasshi 2004; Oct; 124 (04) 245-255
• 5 Guo Q, Wang G, Liu X et al. Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. Brain Res 2009; Jul 7; 1279: 121-130
• 6 Backman JT, Kyrklund C, Neuvonen M et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; Dec; 72 (06) 685-691
• 7 Niemi M, Backman JT, Neuvonen M et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; Mar; 46 (03) 347-351
• 8 Niemi M, Backman JT, Juntti-Patinen L et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005; Aug; 60 (02) 208-217
• 9 Zhang Y, Ding L, Tian Y et al. Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies. Biomed Chromatogr 2008; Aug; 22 (08) 873-878
• 10 Cai S, Huo T, Feng W et al. Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B 2008; Jun 1; 868 (1–2) 83-87
• 11 Zhang J, Cai LJ, Peng WX et al. The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. J Clin Pharm Ther 2011; Apr 24; [Epub ahead of print]
• 12 Lai XS, Yang LP, Li XT et al. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 2009; Nov; 10 (09) 1009-1047
• 13 Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; May; 77 (05) 341-352